AI assistant
Immunovant, Inc. — Director's Dealing 2022
Aug 19, 2022
31436_dirs_2022-08-19_4997336a-ccd2-4329-a90b-c3cb1355ed3a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2022-08-17
Reporting Person: Salzmann Peter (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-17 | Common Stock | A | 451264 | — | Acquired | 1003995 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-08-17 | Stock Option (right to buy) | $4.99 | A | 678592 | Acquired | 2032-08-17 | Common Stock (678592.0) | Direct |
Footnotes
F1: Represents the number of shares underlying restricted stock units awards ("RSUs").
F2: The RSUs vest over four years, with 25% of the RSUs vesting on August 17, 2023 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
F3: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on August 17, 2023 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.